Giorgio Ivan Russo
Papers
13
Total Citations
328
H-Index
11
About
Dr. Giorgio Ivan Russo is a pioneering urologist whose research sits at the intersection of artificial intelligence, precision oncology, and minimally invasive surgery. He has fundamentally advanced how clinicians detect and treat prostate cancer, most notably by demonstrating that biomarkers like PHI and PCA3 can significantly improve the prognostic accuracy of standard active surveillance criteria—a contribution that has earned over 50 citations and reshaped clinical decision-making for men with low-risk disease. Dr. Russo has also been instrumental in refining biopsy techniques, comparing cognitive, robotic, and in-bore MRI-targeted approaches to maximize cancer detection in patients with prior negative biopsies. His work extends to surgical quality, where he proposed the "Radical Nephroureterectomy Tetrafecta" as a novel benchmark for assessing operative success. With over 73 citations for his recent work on AI in andrology, Dr. Russo is a leading voice in the digital transformation of urology. He has also contributed thoughtful analyses on the impact of the COVID-19 pandemic on urology residency training and public interest in robotic surgery, demonstrating a commitment to both clinical excellence and the future of the specialty.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?22 citations · 2020
- 7
- 8
- 9
- 10